GE, PhotoCure expand partnership to U.S. market

GE Healthcare has exercised its exclusive option to license PhotoCure's Hexvix optical molecular imaging agent for the U.S. market.

The U.S. license is an extension of an agreement inked earlier this year that granted the Chalfont St. Giles, U.K.-based firm exclusive global rights outside the Nordic region for Hexvix. The licensing deal is subject to U.S. government approval.

Hexvix is intended for the diagnosis and monitoring of bladder cancer. Oslo, Norway-based PhotoCure will continue to be responsible for manufacturing and Nordic distribution of the agent.

By AuntMinnie.com staff writers
July 31, 2006

Related Reading

GE signs Tulane, July 25, 2006

GE debuts wireless telemetry service, July 24, 2006

DirectPointe partners with GE, InterMountain, July 18, 2006

GE creates new ultrasound units, July 18, 2006

GE, PhotoCure ink optical imaging deal, January 9, 2006

Copyright © 2006 AuntMinnie.com

Page 1 of 1262
Next Page